Company intelligence / Profile preview

GLURES

Milan, Lombardy, Italy

Ownership: Private
Development stage: Other

Overview

GLURES is an Italian biotechnology company specializing in the discovery and development of novel small molecule modulators for glutamate receptors. As a spin-off from the University of Milan, the company leverages advanced computational chemistry and molecular modeling to design ligands targeting ionotropic and metabotropic glutamate receptors. Their research primarily focuses on addressing unmet needs in central nervous system (CNS) disorders, including neurodegenerative diseases and chronic pain. GLURES provides drug discovery services and collaborates with academic and industrial partners to advance its internal pipeline of neuroprotective agents.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

University of Milan

Beyond the preview

Go deeper on GLURES.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLURES.

Explore the full profile